Framework for the Cost-Effectiveness of Secondary Prevention Strategies in Cardiovascular Diseases: A Canadian Theoretical Model-Based Analysis

被引：0
|
作者：
Fanton-Aita, Fiorella [1 ]
Matteau, Alexis [2 ]
Mitchell, Dominic [1 ]
Potter, Brian J. [2 ]
Iliza, Ange Christelle [1 ]
Guertin, Jason R. [3 ]
Dubois, Anick [4 ]
Dube, Marie-Pierre [4 ]
Tardif, Jean-Claude [4 ]
LeLorier, Jacques [1 ]
机构：
[1] Univ Montreal, Montreal, PQ, Canada
[2] CHUM, Montreal, PQ, Canada
[3] McMaster Univ, Hamilton, PQ, Canada
[4] Montreal Heart Inst, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2017年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
585
引用
收藏
页码：353 / 353
页数：1
相关论文
共 50 条
  • [1] Model-based cost-effectiveness analysis of atorvastatin drugs for prevention of cardiovascular diseases in Iran
    Jabbari, Alireza
    Jafari, Abdosaleh
    Hadian, Marziye
    Ghasemi, Mohammad
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2020, 11 (01)
  • [2] Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
    Troche, CJ
    Tacke, J
    Hinzpeter, B
    Danner, M
    Lauterbach, KW
    EUROPEAN HEART JOURNAL, 1998, 19 : C59 - C65
  • [3] Cost-effectiveness analysis of population-based tobacco control strategies in the prevention of cardiovascular diseases in Tanzania
    Ngalesoni, Frida
    Ruhago, George
    Mayige, Mary
    Oliveira, Tiago Cravo
    Robberstad, Bjarne
    Norheim, Ole Frithjof
    Higashi, Hideki
    PLOS ONE, 2017, 12 (08):
  • [4] Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
    Clara Marquina
    Ella Zomer
    Sandra Vargas-Torres
    Sophia Zoungas
    Richard Ofori-Asenso
    Danny Liew
    Zanfina Ademi
    PharmacoEconomics, 2020, 38 : 1095 - 1113
  • [5] Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
    Marquina, Clara
    Zomer, Ella
    Vargas-Torres, Sandra
    Zoungas, Sophia
    Ofori-Asenso, Richard
    Liew, Danny
    Ademi, Zanfina
    PHARMACOECONOMICS, 2020, 38 (10) : 1095 - 1113
  • [6] A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States
    Philip, Sephy
    Chowdhury, Sumita
    Nelson, John R.
    Everett, P. Benjamin
    Hulme-Lowe, Carolyn K.
    Schmier, Jordana K.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 1003 - 1010
  • [7] Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial
    Singh, Kavita
    Crossan, Catriona
    Laba, Tracey-Lea
    Roy, Ambuj
    Hayes, Alison
    Salam, Abdul
    Jan, Stephen
    Lord, Joanne
    Tandon, Nikhil
    Rodgers, Anthony
    Patel, Anushka
    Thom, Simon
    Prabhakaran, Dorairaj
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 262 : 71 - 78
  • [8] Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis
    Portnoy, Allison
    Pedersen, Kine
    Trogstad, Lill
    Hansen, Bo T.
    Feiring, Berit
    Laake, Ida
    Smith, Megan A.
    Sy, Stephen
    Nygard, Mari
    Kim, Jane J.
    Burger, Emily A.
    PREVENTIVE MEDICINE, 2021, 144
  • [9] THE COST-EFFECTIVENESS OF COMBINED VECTOR-CONTROL AND VACCINATION STRATEGIES ON PREVENTION OF DENGUE FEVER: A DYNAMIC MODEL-BASED ANALYSIS
    Knerer, G.
    Currie, C.
    Brailsford, S.
    VALUE IN HEALTH, 2014, 17 (07) : A806 - A806
  • [10] SECONDARY PREVENTION CARDIOVASCULAR PATIENTS IN IRELAND - POPULATION CHARACTERISTICS FOR COST-EFFECTIVENESS ANALYSIS
    O'Donnell, H.
    McCullagh, L.
    Barry, M.
    VALUE IN HEALTH, 2017, 20 (09) : A602 - A602
12345